Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs tocilizumab in Behçet's disease uveitis
2022-001316-26Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Behçet's disease (BD) comparing Adalimumab with Tocilizumab (2 arms). Primary endpoint: Complete ocular remission with low-dose prednisone at week 16. Started Jun 2022; status: active.
02
Drugs
adalimumabtocilizumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on 2022-001316-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001316-26.